


Client report

	No of participants	No of responded participants	Response percentage
Borrelia burgdorferi, antibodies, European origin, January, 1-2025	79	75	94.9 %


Summary Result 1



Summary	Own score	Max score	Own success rate	Difference	AVR success rate
Sample S001	8	8	100 %	1.3 %	98.7 %
Sample S002	8	8	100 %	0.3 %	99.7 %
Average:			100 %	0.8 %	99.2 %


History	Test nr.	Own success rate	Difference	AVR success rate
Round 2024-3	1-1	100 %	3.6 %	96.4 %
Round 2024-3	1-2	87.5 %	-8.9 %	96.4 %
Round 2024-3	1-3	100 %	3.6 %	96.4 %
Round 2024-1	1-1	100 %	1.6 %	98.4 %
Round 2024-1	1-2	100 %	1.6 %	98.4 %
Round 2024-1	1-3	100 %	1.6 %	98.4 %
Round 2023-3	1-1	100 %	5.1 %	94.9 %
Round 2023-3	1-2	100 %	5.1 %	94.9 %

Sample S001 Result 1



Sample S001 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	4	4	100 %	0 %	100 %	89
	BorrAb	-	-	-	-	100 %	5
	BorrAbG	2	2	100 %	0 %	100 %	85
	BorrAbM	2	2	100 %	5.6 %	94.4 %	71
Total:		8	8	100 %	1.3 %	98.7 %	250

Sample S001 Clinical interpretation



Clinical interpretation	Interpretation	Interpretation count	Own score	Max score	Own success rate	Difference	AVR success rate
	☒ Sign of past or on-going infection	34	4	4	100 %	0 %	100 %
	Positive, referred for confirmation	40	-				100 %
	Our laboratory does not give a clinical interpretation to the physician	15	-				-
	Total:	89	4	4	100 %	0 %	100 %

